Navidea Biopharmaceuticals Earnings: Here’s Why Investors are Not Excited Now

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 5.72%.

Navidea Biopharmaceuticals Inc Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.09 in the quarter versus EPS of $-0.06 in the year-earlier quarter.

Revenue: Rose 233.33% to $200,000 from the year-earlier quarter.

Actual vs. Wall St. Expectations: Navidea Biopharmaceuticals Inc reported adjusted EPS loss of $0.09 per share. By that measure, the company missed the mean analyst estimate of $-0.07. It beat the average revenue estimate of $0.

Quoting Management: “The most significant event for Navidea this quarter was the launch of our first product, Lymphoseek®. Our launch is off to a great start and we are advancing our innovative portfolio with the initiation of the Phase 3 study of NAV4694 in Alzheimer’s disease. During the second half of 2013, we expect to further enhance our long-term growth with additional value enhancing pipeline events,” said Dr. Mark Pykett, Navidea CEO

Key Stats (on next page)…

Revenue decreased 0% from $0 in the previous quarter. EPS increased to $-0.09 in the quarter versus EPS of $-0.06 in the previous quarter.

Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a loss of $0.06 and has not changed. For the current year, the average estimate is a loss of $0.23, which is the same with that ninety days ago.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]